Co-Diagnostics (DE:C970)
NASDAQ:C970
C970 Stock Chart & Stats
€0.26
-€0.13(-13.68%)
At close: 4:00 PM EST
€0.26
-€0.13(-13.68%)
Day’s Range― - ―
52-Week Range€5.16 - €36.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€18.01M
Enterprise Value€3.32M
Total Cash (Recent Filing)€8.23M
Total Debt (Recent Filing)€2.03M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.26
Shares Outstanding3,685,314
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.36
Revenue Forecast (FY)€471.11K
Bulls Say, Bears Say
Bulls Say
Regulatory Progress — Upper Respiratory Enrollment & 510(k) TargetCompleting a >1,400‑patient upper respiratory study and targeting a 510(k) for Flu A/B/RSV is a durable regulatory milestone. A successful CLIA‑waived or 510(k) clearance enables point‑of‑care placement, recurring consumable demand and broader lab adoption, materially improving long‑term commercial scalability if executed.
Established India Manufacturing & Commercial Footprint (CoSara)Having an owned manufacturing foothold and multiple CDSCO clearances in India gives Co‑Diagnostics durable access to a large South Asia market (~$13B TAM). Regulatory approvals plus hundreds of lab customers shorten commercialization cycles, support recurring reagent sales, and reduce dependency on third‑party channels over time.
Low Financial LeverageModest debt levels provide structural financial flexibility versus highly leveraged peers. Low leverage reduces immediate solvency risk and preserves optionality to raise debt or structured financing to fund manufacturing or regulatory milestones, improving the company’s ability to support execution without being overburdened by interest costs.
Bears Say
Severe Revenue Collapse And Limited Commercial ScaleThe precipitous decline from nearly $98M to under $1M TTM reflects a loss of commercial scale. Such a small revenue base cannot absorb fixed costs, undermines operating leverage and makes margin recovery and sustainable profitability dependent on substantial new product wins or market penetration that will take many quarters to materialize.
Persistent Cash Burn And Negative Operating Cash FlowSustained negative OCF (~-$28.2M TTM) and a cash balance near $8.2M create a durable liquidity constraint. At current burn rates and low revenues, the company will likely need external funding, which can be dilutive or restrictive, and limited cash constrains commercialization, hiring, and manufacturing scale‑up timing.
Ongoing Operating Losses And Execution Risk Requiring CapitalQuarterly losses and widening adjusted EBITDA losses highlight structural negative profitability. Coupled with higher R&D spend, unfinished manufacturing automation and clinical dependencies (e.g., COVID prevalence affecting submissions), this creates execution risk: planned commercialization and scale depend on both successful operations and new capital, which is not assured.
Co-Diagnostics News
C970 FAQ
What was Co-Diagnostics’s price range in the past 12 months?
Co-Diagnostics lowest stock price was €5.16 and its highest was €36.00 in the past 12 months.
What is Co-Diagnostics’s market cap?
Co-Diagnostics’s market cap is €18.01M.
When is Co-Diagnostics’s upcoming earnings report date?
Co-Diagnostics’s upcoming earnings report date is Aug 06, 2026 which is in 60 days.
How were Co-Diagnostics’s earnings last quarter?
Co-Diagnostics released its earnings results on May 14, 2026. The company reported -€3.523 earnings per share for the quarter, missing the consensus estimate of N/A by -€3.523.
Is Co-Diagnostics overvalued?
According to Wall Street analysts Co-Diagnostics’s price is currently Overvalued.
Does Co-Diagnostics pay dividends?
Co-Diagnostics does not currently pay dividends.
What is Co-Diagnostics’s EPS estimate?
Co-Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Co-Diagnostics have?
Co-Diagnostics has 3,685,314 shares outstanding.
What happened to Co-Diagnostics’s price movement after its last earnings report?
Co-Diagnostics reported an EPS of -€3.523 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Co-Diagnostics?
Currently, no hedge funds are holding shares in DE:C970
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
C970 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated meaningful operational and regulatory progress across multiple strategic fronts — completed upper respiratory enrollment (>1,400 patients), India manufacturing license and expanded TAM (~$13B), TB clinical start timing, land allocation in Saudi Arabia, and manufacturing automation plans (~4x efficiency). However, the company still reports very limited absolute revenue, a negative gross margin, widening net loss and adjusted EBITDA losses, and a substantial cash decline to $8.2M with an anticipated need for additional capital. Program-level uncertainties (COVID prevalence affecting submission scope), unfinished manufacturing rollouts and no assurance on strategic transactions temper the positive operational milestones. Overall, operational momentum is clear, but financial constraints and execution risks balance the outlook.View all DE:C970 earnings summariesSintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Options Prices
Currently, No data available
---